Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| OTONOMY, INC.OTIC · Entity 116495 | Director | June 21, 2022 | June 23, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
OTONOMY, INC.
Report date June 21, 2022 · Filed June 23, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.95 · Expires 2032-06-20 | Direct | 27,500 |
Reported balance
After 2022-06-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-21 · Grant · Acquired 27,500 · Balance 27,500 F1: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date, and (ii) the date of the Issuer's next annual meeting of stockholders occurring after the grant date, provided that the Reporting Person remains a service provider through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date, and (ii) the date of the Issuer's next annual meeting of stockholders occurring after the grant date, provided that the Reporting Person remains a service provider through such date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Janux Therapeutics, Inc.
Report date September 13, 2024 · Filed October 24, 2024
Section 16 reporting ended · disclosed 2024-10-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,000 |
Ending reported balance
After 2024-09-13 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2024-09-13 · Exercise / conversion · Acquired 1,868 · Balance 8,868 Row 2 · 2024-09-13 · Exercise / conversion · Acquired 778 · Balance 9,646 Row 3 · 2024-09-13 · Exercise / conversion · Acquired 778 · Balance 10,424 Row 4 · 2024-09-13 · Exercise / conversion · Acquired 391 · Balance 10,815 Row 5 · 2024-09-13 · Sale · Disposed 3,815 · Balance 7,000 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2027-07-19 | Direct | 27,138 |
Reported balance
After 2024-09-13 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2024-09-13 · Exercise / conversion · Disposed 1,868 · Balance 27,138 F4: Immediately exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.73 · Expires 2027-07-19 | Direct | 11,308 |
Reported balance
After 2024-09-13 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2024-09-13 · Exercise / conversion · Disposed 778 · Balance 11,308 F4: Immediately exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.22 · Expires 2027-07-19 | Direct | 11,308 |
Reported balance
After 2024-09-13 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2024-09-13 · Exercise / conversion · Disposed 778 · Balance 11,308 F4: Immediately exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.80 · Expires 2027-07-19 | Direct | 7,682 |
Reported balance
After 2024-09-13 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2024-09-13 · Exercise / conversion · Disposed 391 · Balance 7,682 F4: Immediately exercisable. |
| Common StockSEC Table I · non-derivative | IndirectBy Avalon Ventures XI, L.P. | 2,959,175 |
Reported balance
Holding disclosure · report date 2024-09-13 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 2,959,175 F1: The securities are directly held by Avalon Ventures XI, L.P. ("Avalon Ventures"). Avalon Ventures XI GP, LLC ("Avalon XI GP") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. The Reporting Person is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. The Reporting Persons disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy Avalon BioVentures I, LP | 573,227 |
Reported balance
Holding disclosure · report date 2024-09-13 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 573,227 F2: The securities are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. The Reporting Person is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. The Reporting Persons disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy Avalon BioVentures SPV I, L.P. | 3,021,414 |
Reported balance
Holding disclosure · report date 2024-09-13 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 3,021,414 F3: The securities are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. The Reporting Person is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. The Reporting Persons disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities are directly held by Avalon Ventures XI, L.P. ("Avalon Ventures"). Avalon Ventures XI GP, LLC ("Avalon XI GP") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. The Reporting Person is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. The Reporting Persons disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
F2: The securities are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. The Reporting Person is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. The Reporting Persons disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
F3: The securities are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. The Reporting Person is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. The Reporting Persons disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
F4: Immediately exercisable.
Synthorx, Inc.
Report date January 23, 2020 · Filed January 24, 2020
Section 16 reporting ended · disclosed 2020-01-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Avalon Ventures X, L.P. | 0 |
Reported balance
After 2020-01-23 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2020-01-23 · Other · Disposed 150,000 · Balance 0 F1: The Reporting Person is a managing member of Avalon Ventures X GP LLC and Avalon Ventures X SPV GP LLC, the general partners of Avalon Ventures X, L.P. and Avalon X SPV I, L.P., and shares voting and investment power with respect to the shares held by Avalon Ventures X, L.P. and Avalon X SPV I, L.P. The Reporting Person disclaims beneficial ownership of the shares held by Avalon Ventures X, L.P., Avalon Ventures X GP LLC and Avalon X SPV I, L.P., except to the extent of his actual pecuniary interest therein if any. |
| Common StockSEC Table I · non-derivative | IndirectBy Avalon Ventures X GP, LLC | 0 |
Reported balance
After 2020-01-23 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2020-01-23 · Other · Disposed 448,567 · Balance 0 F1: The Reporting Person is a managing member of Avalon Ventures X GP LLC and Avalon Ventures X SPV GP LLC, the general partners of Avalon Ventures X, L.P. and Avalon X SPV I, L.P., and shares voting and investment power with respect to the shares held by Avalon Ventures X, L.P. and Avalon X SPV I, L.P. The Reporting Person disclaims beneficial ownership of the shares held by Avalon Ventures X, L.P., Avalon Ventures X GP LLC and Avalon X SPV I, L.P., except to the extent of his actual pecuniary interest therein if any. |
| Common StockSEC Table I · non-derivative | IndirectBy Avalon X SPV I, L.P. | 0 |
Reported balance
After 2020-01-23 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2020-01-23 · Other · Disposed 1,682,086 · Balance 0 F1: The Reporting Person is a managing member of Avalon Ventures X GP LLC and Avalon Ventures X SPV GP LLC, the general partners of Avalon Ventures X, L.P. and Avalon X SPV I, L.P., and shares voting and investment power with respect to the shares held by Avalon Ventures X, L.P. and Avalon X SPV I, L.P. The Reporting Person disclaims beneficial ownership of the shares held by Avalon Ventures X, L.P., Avalon Ventures X GP LLC and Avalon X SPV I, L.P., except to the extent of his actual pecuniary interest therein if any. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.00 · Expires 2028-12-05 | Direct | 0 |
Reported balance
After 2020-01-23 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-01-23 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: This option, which provided for vesting of the shares in equal monthly installments over the 12 months following December 6, 2018, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $1,710,000.00, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.40 · Expires 2029-06-06 | Direct | 0 |
Reported balance
After 2020-01-23 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-01-23 · Disposition to issuer · Disposed 15,335 · Balance 0 F3: This option, which provided for vesting of the shares in equal monthly installments over the 12 months following June 7, 2019, such that the option would be fully vested on the date of the Issuer's next annual stockholder meeting, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $852,626.00, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68). |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person is a managing member of Avalon Ventures X GP LLC and Avalon Ventures X SPV GP LLC, the general partners of Avalon Ventures X, L.P. and Avalon X SPV I, L.P., and shares voting and investment power with respect to the shares held by Avalon Ventures X, L.P. and Avalon X SPV I, L.P. The Reporting Person disclaims beneficial ownership of the shares held by Avalon Ventures X, L.P., Avalon Ventures X GP LLC and Avalon X SPV I, L.P., except to the extent of his actual pecuniary interest therein if any.
F2: This option, which provided for vesting of the shares in equal monthly installments over the 12 months following December 6, 2018, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $1,710,000.00, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68).
F3: This option, which provided for vesting of the shares in equal monthly installments over the 12 months following June 7, 2019, such that the option would be fully vested on the date of the Issuer's next annual stockholder meeting, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $852,626.00, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 18, 2024 Filed Oct 18, 2024 22:51 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 553,219 | $44.75 | $24,756,550.25 |
DisclosureSEC source: 0001415889-24-025436 · form4-10182024_101021.xml · nonDerivative · entry 25 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Avalon BioVentures SPV I, L.P. Disclosed balance after: 2,115,373 F11 · kind: Shares sold in a private transaction pursuant to a stock purchase agreement dated September 12, 2024. The closing of the transaction was subject to certain customary conditions to closing, including the expiration or earlier termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. The closing conditions were satisfied, and the transaction closed, on October 18, 2024. F4 · ownership.nature: The securities are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 18, 2024 Filed Oct 18, 2024 22:51 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 104,957 | $44.75 | $4,696,825.75 |
DisclosureSEC source: 0001415889-24-025436 · form4-10182024_101021.xml · nonDerivative · entry 24 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Avalon BioVentures I, LP Disclosed balance after: 401,321 F11 · kind: Shares sold in a private transaction pursuant to a stock purchase agreement dated September 12, 2024. The closing of the transaction was subject to certain customary conditions to closing, including the expiration or earlier termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. The closing conditions were satisfied, and the transaction closed, on October 18, 2024. F3 · ownership.nature: The securities are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 18, 2024 Filed Oct 18, 2024 22:51 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 541,824 | $44.75 | $24,246,624.00 |
DisclosureSEC source: 0001415889-24-025436 · form4-10182024_101021.xml · nonDerivative · entry 23 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,071,799 F11 · kind: Shares sold in a private transaction pursuant to a stock purchase agreement dated September 12, 2024. The closing of the transaction was subject to certain customary conditions to closing, including the expiration or earlier termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. The closing conditions were satisfied, and the transaction closed, on October 18, 2024. F2 · ownership.direct: The securities are directly held by Avalon Ventures XI, L.P. ("Avalon Ventures"). Avalon Ventures XI GP, LLC ("Avalon XI GP") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 18, 2024 Filed Oct 18, 2024 22:51 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 15,788 | $51.18 | $808,029.84 |
DisclosureSEC source: 0001415889-24-025436 · form4-10182024_101021.xml · nonDerivative · entry 22 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Avalon BioVentures SPV I, L.P. Disclosed balance after: 2,668,592 F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.97 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The securities are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 18, 2024 Filed Oct 18, 2024 22:51 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 2,995 | $51.18 | $153,284.10 |
DisclosureSEC source: 0001415889-24-025436 · form4-10182024_101021.xml · nonDerivative · entry 21 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Avalon BioVentures I, LP Disclosed balance after: 506,278 F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.97 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The securities are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 18, 2024 Filed Oct 18, 2024 22:51 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 15,462 | $51.18 | $791,345.16 |
DisclosureSEC source: 0001415889-24-025436 · form4-10182024_101021.xml · nonDerivative · entry 20 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,613,623 F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.97 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: The securities are directly held by Avalon Ventures XI, L.P. ("Avalon Ventures"). Avalon Ventures XI GP, LLC ("Avalon XI GP") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 18, 2024 Filed Oct 18, 2024 22:51 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 104,892 | $50.30 | $5,276,067.60 |
DisclosureSEC source: 0001415889-24-025436 · form4-10182024_101021.xml · nonDerivative · entry 19 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Avalon BioVentures SPV I, L.P. Disclosed balance after: 2,684,380 F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.86 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The securities are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 18, 2024 Filed Oct 18, 2024 22:51 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 19,900 | $50.30 | $1,000,970.00 |
DisclosureSEC source: 0001415889-24-025436 · form4-10182024_101021.xml · nonDerivative · entry 18 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Avalon BioVentures I, LP Disclosed balance after: 509,273 F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.86 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The securities are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 18, 2024 Filed Oct 18, 2024 22:51 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 102,732 | $50.30 | $5,167,419.60 |
DisclosureSEC source: 0001415889-24-025436 · form4-10182024_101021.xml · nonDerivative · entry 17 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,629,085 F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.86 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: The securities are directly held by Avalon Ventures XI, L.P. ("Avalon Ventures"). Avalon Ventures XI GP, LLC ("Avalon XI GP") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 17, 2024 Filed Oct 18, 2024 22:51 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionStock Option (right to buy) · Derivative | 237 | $0.00 Strike: $39.80 | $0.00 |
DisclosureSEC source: 0001415889-24-025436 · form4-10182024_101021.xml · derivative · entry 33 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,072 Underlying: Common Stock · 237 shares Expires 2027-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: Immediately exercisable. F6 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| October 17, 2024 Filed Oct 18, 2024 22:51 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionStock Option (right to buy) · Derivative | 348 | $0.00 Strike: $13.22 | $0.00 |
DisclosureSEC source: 0001415889-24-025436 · form4-10182024_101021.xml · derivative · entry 32 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,142 Underlying: Common Stock · 348 shares Expires 2027-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: Immediately exercisable. F6 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| October 17, 2024 Filed Oct 18, 2024 22:51 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionStock Option (right to buy) · Derivative | 348 | $0.00 Strike: $10.73 | $0.00 |
DisclosureSEC source: 0001415889-24-025436 · form4-10182024_101021.xml · derivative · entry 31 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,142 Underlying: Common Stock · 348 shares Expires 2027-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: Immediately exercisable. F6 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| October 17, 2024 Filed Oct 18, 2024 22:51 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionStock Option (right to buy) · Derivative | 836 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001415889-24-025436 · form4-10182024_101021.xml · derivative · entry 30 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,940 Underlying: Common Stock · 836 shares Expires 2027-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: Immediately exercisable. F6 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| October 17, 2024 Filed Oct 18, 2024 22:51 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 1,843 | $50.02 | $92,186.86 |
DisclosureSEC source: 0001415889-24-025436 · form4-10182024_101021.xml · nonDerivative · entry 16 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,371 F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.97 to $50.18 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F6 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| October 17, 2024 Filed Oct 18, 2024 22:51 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionCommon Stock | 237 | $39.80 | $9,432.60 |
DisclosureSEC source: 0001415889-24-025436 · form4-10182024_101021.xml · nonDerivative · entry 15 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,214 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| October 17, 2024 Filed Oct 18, 2024 22:51 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionCommon Stock | 348 | $13.22 | $4,600.56 |
DisclosureSEC source: 0001415889-24-025436 · form4-10182024_101021.xml · nonDerivative · entry 14 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,977 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| October 17, 2024 Filed Oct 18, 2024 22:51 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionCommon Stock | 348 | $10.73 | $3,734.04 |
DisclosureSEC source: 0001415889-24-025436 · form4-10182024_101021.xml · nonDerivative · entry 13 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,629 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| October 17, 2024 Filed Oct 18, 2024 22:51 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionCommon Stock | 836 | $17.00 | $14,212.00 |
DisclosureSEC source: 0001415889-24-025436 · form4-10182024_101021.xml · nonDerivative · entry 12 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,281 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 22:51 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionStock Option (right to buy) · Derivative | 1,407 | $0.00 Strike: $39.80 | $0.00 |
DisclosureSEC source: 0001415889-24-025436 · form4-10182024_101021.xml · derivative · entry 29 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,309 Underlying: Common Stock · 1,407 shares Expires 2027-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: Immediately exercisable. F6 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 22:51 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionStock Option (right to buy) · Derivative | 2,070 | $0.00 Strike: $13.22 | $0.00 |
DisclosureSEC source: 0001415889-24-025436 · form4-10182024_101021.xml · derivative · entry 28 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,490 Underlying: Common Stock · 2,070 shares Expires 2027-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: Immediately exercisable. F6 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 22:51 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionStock Option (right to buy) · Derivative | 2,070 | $0.00 Strike: $10.73 | $0.00 |
DisclosureSEC source: 0001415889-24-025436 · form4-10182024_101021.xml · derivative · entry 27 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,490 Underlying: Common Stock · 2,070 shares Expires 2027-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: Immediately exercisable. F6 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 22:51 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionStock Option (right to buy) · Derivative | 4,968 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001415889-24-025436 · form4-10182024_101021.xml · derivative · entry 26 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,776 Underlying: Common Stock · 4,968 shares Expires 2027-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: Immediately exercisable. F6 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 22:51 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 10,957 | $50.80 | $556,615.60 |
DisclosureSEC source: 0001415889-24-025436 · form4-10182024_101021.xml · nonDerivative · entry 11 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,445 F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.76 to $51.05 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F6 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 22:51 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionCommon Stock | 1,407 | $39.80 | $55,998.60 |
DisclosureSEC source: 0001415889-24-025436 · form4-10182024_101021.xml · nonDerivative · entry 10 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,402 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 22:51 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionCommon Stock | 2,070 | $13.22 | $27,365.40 |
DisclosureSEC source: 0001415889-24-025436 · form4-10182024_101021.xml · nonDerivative · entry 9 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,995 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 22:51 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionCommon Stock | 2,070 | $10.73 | $22,211.10 |
DisclosureSEC source: 0001415889-24-025436 · form4-10182024_101021.xml · nonDerivative · entry 8 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,925 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 22:51 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionCommon Stock | 4,968 | $17.00 | $84,456.00 |
DisclosureSEC source: 0001415889-24-025436 · form4-10182024_101021.xml · nonDerivative · entry 7 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,855 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 22:51 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 30,094 | $50.61 | $1,523,057.34 |
DisclosureSEC source: 0001415889-24-025436 · form4-10182024_101021.xml · nonDerivative · entry 6 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Avalon BioVentures SPV I, LP Disclosed balance after: 2,789,272 F5 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $50.46 to $51.25 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The securities are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 22:51 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 5,710 | $50.61 | $288,983.10 |
DisclosureSEC source: 0001415889-24-025436 · form4-10182024_101021.xml · nonDerivative · entry 5 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Avalon BioVentures I, LP Disclosed balance after: 529,173 F5 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $50.46 to $51.25 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The securities are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 22:51 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 29,474 | $50.61 | $1,491,679.14 |
DisclosureSEC source: 0001415889-24-025436 · form4-10182024_101021.xml · nonDerivative · entry 4 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,731,817 F5 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $50.46 to $51.25 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: The securities are directly held by Avalon Ventures XI, L.P. ("Avalon Ventures"). Avalon Ventures XI GP, LLC ("Avalon XI GP") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 22:51 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 61,445 | $49.69 | $3,053,202.05 |
DisclosureSEC source: 0001415889-24-025436 · form4-10182024_101021.xml · nonDerivative · entry 3 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Avalon BioVentures SPV I, L.P. Disclosed balance after: 2,819,366 F1 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $49.50 to $50.45 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The securities are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 22:51 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 11,657 | $49.69 | $579,236.33 |
DisclosureSEC source: 0001415889-24-025436 · form4-10182024_101021.xml · nonDerivative · entry 2 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Avalon BioVentures I, LP Disclosed balance after: 534,883 F1 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $49.50 to $50.45 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The securities are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 22:51 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 60,179 | $49.69 | $2,990,294.51 |
DisclosureSEC source: 0001415889-24-025436 · form4-10182024_101021.xml · nonDerivative · entry 1 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,761,291 F1 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $49.50 to $50.45 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: The securities are directly held by Avalon Ventures XI, L.P. ("Avalon Ventures"). Avalon Ventures XI GP, LLC ("Avalon XI GP") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| September 30, 2024 Filed Oct 1, 2024 00:49 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionStock Option (right to buy) · Derivative | 123 | $0.00 Strike: $39.80 | $0.00 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · derivative · entry 30 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,716 Underlying: Common Stock · 123 shares Expires 2027-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Immediately exercisable. F8 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| September 30, 2024 Filed Oct 1, 2024 00:49 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionStock Option (right to buy) · Derivative | 181 | $0.00 Strike: $13.22 | $0.00 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · derivative · entry 29 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,560 Underlying: Common Stock · 181 shares Expires 2027-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Immediately exercisable. F8 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| September 30, 2024 Filed Oct 1, 2024 00:49 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionStock Option (right to buy) · Derivative | 181 | $0.00 Strike: $10.73 | $0.00 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · derivative · entry 28 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,560 Underlying: Common Stock · 181 shares Expires 2027-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Immediately exercisable. F8 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| September 30, 2024 Filed Oct 1, 2024 00:49 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionStock Option (right to buy) · Derivative | 434 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · derivative · entry 27 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,744 Underlying: Common Stock · 434 shares Expires 2027-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Immediately exercisable. F8 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| September 30, 2024 Filed Oct 1, 2024 00:49 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 958 | $46.24 | $44,297.92 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · nonDerivative · entry 22 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,887 F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.24 to $46.31 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F8 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| September 30, 2024 Filed Oct 1, 2024 00:49 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionCommon Stock | 123 | $39.80 | $4,895.40 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · nonDerivative · entry 21 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,845 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| September 30, 2024 Filed Oct 1, 2024 00:49 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionCommon Stock | 181 | $13.22 | $2,392.82 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · nonDerivative · entry 20 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,722 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| September 30, 2024 Filed Oct 1, 2024 00:49 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionCommon Stock | 181 | $10.73 | $1,942.13 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · nonDerivative · entry 19 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,541 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| September 30, 2024 Filed Oct 1, 2024 00:49 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionCommon Stock | 434 | $17.00 | $7,378.00 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · nonDerivative · entry 18 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,360 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 00:49 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionStock Option (right to buy) · Derivative | 234 | $0.00 Strike: $39.80 | $0.00 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · derivative · entry 26 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,839 Underlying: Common Stock · 234 shares Expires 2027-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Immediately exercisable. F8 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 00:49 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionStock Option (right to buy) · Derivative | 345 | $0.00 Strike: $13.22 | $0.00 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · derivative · entry 25 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,741 Underlying: Common Stock · 345 shares Expires 2027-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Immediately exercisable. F8 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 00:49 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionStock Option (right to buy) · Derivative | 345 | $0.00 Strike: $10.73 | $0.00 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · derivative · entry 24 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,741 Underlying: Common Stock · 345 shares Expires 2027-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Immediately exercisable. F8 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 00:49 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionStock Option (right to buy) · Derivative | 828 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · derivative · entry 23 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,178 Underlying: Common Stock · 828 shares Expires 2027-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Immediately exercisable. F8 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 00:49 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 1,826 | $46.19 | $84,342.94 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · nonDerivative · entry 17 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,926 F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.11 to $46.22 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F8 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 00:49 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionCommon Stock | 234 | $39.80 | $9,313.20 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · nonDerivative · entry 16 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,752 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 00:49 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionCommon Stock | 345 | $13.22 | $4,560.90 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · nonDerivative · entry 15 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,518 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 00:49 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionCommon Stock | 345 | $10.73 | $3,701.85 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · nonDerivative · entry 14 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,173 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.